Necrolytic Acral Erythema Medication

  • Author: Katherine Z Holcomb, MD, MPH; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Aug 2, 2011
 

Medication Summary

The goal of treatment is to decrease the burning and pruritus and improve the appearance of the lesions of necrolytic acral erythema. Zinc sulfate,[19] amino acid supplementation, and interferon alfa have been successful in treating necrolytic acral erythema. Topical tacrolimus has been reported as an effective treatment for necrolytic acral erythema.[20]

Next

Minerals

Class Summary

Act as enzyme cofactors and are required in metabolic processing.

View full drug information

Zinc

 

Use sulfate or gluconate zinc salt. Zinc sulfate 4.4 mg = 1 mg of elemental zinc. Zinc gluconate 7.1 mg = 1 mg of elemental zinc.

Previous
Next

Interferons

Class Summary

Naturally occurring compounds that have both antiviral and immunomodulatory effects.

View full drug information

Peginterferon alfa-2a (Pegasys)

 

Used in combination with ribavirin to treat patients with chronic hepatitis C who have compensated liver disease and have not previously received interferon alfa. Consists of interferon alfa-2a attached to a 40-kd branched PEG molecule. Predominantly metabolized by the liver.

View full drug information

Peginterferon alfa-2b (PEG Intron)

 

Escherichia coli recombinant product. Used to treat chronic hepatitis C in patients not previously treated with interferon alfa who have compensated liver disease. Exerts cellular activities by binding to specific membrane receptors on cell surface, which, in turn, may suppress cell proliferation and may enhance phagocytic activity of macrophages. May also increase cytotoxicity of lymphocytes for target cells and inhibit virus replication in virus-infected cells.

Previous
Next

Nucleoside Analogs

Class Summary

Drugs that interfere with the production of DNA and RNA.

View full drug information

Ribavirin (Virazole)

 

Antiviral nucleoside analog. Chemical name is D -ribofuranosyl-1H-1,2,4-triazole-3-carboxamide. Given alone, has little effect on the course of hepatitis C. When given with interferon, significantly augments rate of sustained virologic response.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Katherine Z Holcomb, MD, MPH  Staff Physician, Department of Dermatology, Naval Hospital Camp Lejeune; Clinical Instructor, Department of Family Medicine, Naval Hospital Camp Lejeune

Katherine Z Holcomb, MD, MPH is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Coauthor(s)

Noah S Scheinfeld, MD, JD, FAAD  Assistant Clinical Professor, Department of Dermatology, Columbia University College of Physicians and Surgeons; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, and New York Eye and Ear Infirmary; Private Practice

Noah S Scheinfeld, MD, JD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Optigenex Consulting fee Independent contractor

Specialty Editor Board

Timothy McCalmont, MD  Director, UCSF Dermatopathology Service, Professor of Clinical Pathology and Dermatology, Departments of Pathology and Dermatology, University of California at San Francisco; Editor-in-Chief, Journal of Cutaneous Pathology

Timothy McCalmont, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, American Society of Dermatopathology, California Medical Association, College of American Pathologists, and United States and Canadian Academy of Pathology

Disclosure: Apsara Consulting fee Independent contractor

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Camila K Janniger, MD  Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. el Darouti M, Abu el Ela M. Necrolytic acral erythema: a cutaneous marker of viral hepatitis C. Int J Dermatol. Apr 1996;35(4):252-6. [Medline].

  2. Tabibian JH, Gerstenblith MR, Tedford RJ, Junkins-Hopkins JM, Abuav R. Necrolytic Acral Erythema as a Cutaneous Marker of Hepatitis C: Report of Two Cases and Review. Dig Dis Sci. May 26 2010;[Medline].

  3. Abdallah MA, Ghozzi MY, Monib HA, et al. Necrolytic acral erythema: a cutaneous sign of hepatitis C virus infection. J Am Acad Dermatol. Aug 2005;53(2):247-51. [Medline].

  4. Khanna VJ, Shieh S, Benjamin J, et al. Necrolytic acral erythema associated with hepatitis C: effective treatment with interferon alfa and zinc. Arch Dermatol. Jun 2000;136(6):755-7. [Medline].

  5. Wu YH, Tu ME, Lee CS, Lin YC. Necrolytic acral erythema without hepatitis C infection. J Cutan Pathol. Mar 2009;36(3):355-8. [Medline].

  6. El-Darouti MA, Mashaly HM, El-Nabarawy E, et al. Leukocytoclastic vasculitis and necrolytic acral erythema in patients with hepatitis C infection: do viral load and viral genotype play a role?. J Am Acad Dermatol. Aug 2010;63(2):259-65. [Medline].

  7. Panda S, Lahiri K. Seronegative necrolytic acral erythema: a distinct clinical subset?. Indian J Dermatol. Jul-Sep 2010;3:259-61. [Medline].

  8. Patel U, Loyd A, Patel R, Meehan S, Kundu R. Necrolytic acral erythema. Dermatol Online J. Nov 2010;11:15. [Medline].

  9. El-Ghandour TM, Sakr MA, El-Sebai H, El-Gammal TF, El-Sayed MH. Necrolytic acral erythema in Egyptian patients with hepatitis C virus infection. J Gastroenterol Hepatol. Jul 2006;21(7):1200-6. [Medline].

  10. Williams J. Necrolytic acral erythema. DermAtlas. Available at http://dermatlas.med.jhmi.edu/derm/result.cfm?Diagnosis=178630456. Accessed January 25, 2007.

  11. Janjua SA. Necrolytic acral erythema. DermAtlas. Available at http://dermatlas.med.jhmi.edu/derm/result.cfm?Diagnosis=178630456. Accessed January 25, 2007.

  12. Abdallah MA, Ghozzi MY, Monib HA, et al. Histological study of necrolytic acral erythema. J Ark Med Soc. Apr 2004;100(10):354-5. [Medline].

  13. Hivnor CM, Yan AC, Junkins-Hopkins JM, Honig PJ. Necrolytic acral erythema: response to combination therapy with interferon and ribavirin. J Am Acad Dermatol. May 2004;50(5 Suppl):S121-4. [Medline].

  14. Nofal AA, Nofal E, Attwa E, El-Assar O, Assaf M. Necrolytic acral erythema: a variant of necrolytic migratory erythema or a distinct entity?. Int J Dermatol. Nov 2005;44(11):916-21. [Medline].

  15. Najarian DJ, Lefkowitz I, Balfour E, Pappert AS, Rao BK. Zinc deficiency associated with necrolytic acral erythema. J Am Acad Dermatol. Nov 2006;55(5 Suppl):S108-10. [Medline].

  16. Najarian DJ, Najarian JS, Rao BK, Pappert AS. Hypozincemia and hyperzincuria associated with necrolytic acral erythema. Int J Dermatol. Jul 2008;47(7):709-11. [Medline].

  17. Bentley D, Andea A, Holzer A, Elewski B. Lack of classic histology should not prevent diagnosis of necrolytic acral erythema. J Am Acad Dermatol. Mar 2009;60(3):504-7. [Medline].

  18. Abdallah MA, Hull C, Horn TD. Necrolytic acral erythema: a patient from the United States successfully treated with oral zinc. Arch Dermatol. Jan 2005;141(1):85-7. [Medline].

  19. de Carvalho Fantini B, Matsumoto FY, Arnone M, Sotto MN, Junior WB. Necrolytic acral erythema successfully treated with oral zinc. Int J Dermatol. Aug 2008;47(8):872-3. [Medline].

  20. Manzur A, Siddiqui AH. Necrolytic acral erythema: successful treatment with topical tacrolimus ointment. Int J Dermatol. Oct 2008;47(10):1073-5. [Medline].

 
Previous
Next
 
Plaque of necrolytic acral erythema on the ankle of a male.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.